WO2017197141A3 - Targeted treatment of androgenic alopecia - Google Patents

Targeted treatment of androgenic alopecia Download PDF

Info

Publication number
WO2017197141A3
WO2017197141A3 PCT/US2017/032202 US2017032202W WO2017197141A3 WO 2017197141 A3 WO2017197141 A3 WO 2017197141A3 US 2017032202 W US2017032202 W US 2017032202W WO 2017197141 A3 WO2017197141 A3 WO 2017197141A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleases
androgenic alopecia
polynucleotides encoding
targeted treatment
domain
Prior art date
Application number
PCT/US2017/032202
Other languages
French (fr)
Other versions
WO2017197141A2 (en
Inventor
Tanja MEYER
Original Assignee
Sangamo Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sangamo Therapeutics, Inc. filed Critical Sangamo Therapeutics, Inc.
Publication of WO2017197141A2 publication Critical patent/WO2017197141A2/en
Publication of WO2017197141A3 publication Critical patent/WO2017197141A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y503/00—Intramolecular oxidoreductases (5.3)
    • C12Y503/99—Other intramolecular oxidoreductases (5.3.99)
    • C12Y503/99002—Prostaglandin-D synthase (5.3.99.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Disclosed herein are methods and compositions for inactivating genes associated with androgenic alopecia, using engineered nucleases comprising a DNA binding domain and a cleavage domain or cleavage half-domain in conditions able to preserve cell viability. Polynucleotides encoding nucleases, vectors comprising polynucleotides encoding nucleases, and cells comprising polynucleotides encoding nucleases and/or cells comprising nucleases are also provided.
PCT/US2017/032202 2016-05-13 2017-05-11 Targeted treatment of androgenic alopecia WO2017197141A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662335952P 2016-05-13 2016-05-13
US62/335,952 2016-05-13

Publications (2)

Publication Number Publication Date
WO2017197141A2 WO2017197141A2 (en) 2017-11-16
WO2017197141A3 true WO2017197141A3 (en) 2017-12-07

Family

ID=60267132

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/032202 WO2017197141A2 (en) 2016-05-13 2017-05-11 Targeted treatment of androgenic alopecia

Country Status (1)

Country Link
WO (1) WO2017197141A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017367722B2 (en) 2016-12-01 2024-02-01 Sangamo Therapeutics, Inc. Tau modulators and methods and compositions for delivery thereof
SG11202103314QA (en) * 2018-10-02 2021-04-29 Sangamo Therapeutics Inc Engineered genetic modulators
US20240400991A1 (en) * 2021-09-24 2024-12-05 Oregon Health & Science University Immune cells with reduced androgen receptor (ar) level, and methods of their use to enhance anti-cancer therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088188A2 (en) * 2000-05-18 2001-11-22 Nihon University, School Juridical Person Method for examining ischemic conditions
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses
WO2015117021A1 (en) * 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001088188A2 (en) * 2000-05-18 2001-11-22 Nihon University, School Juridical Person Method for examining ischemic conditions
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses
WO2015117021A1 (en) * 2014-01-31 2015-08-06 Factor Bioscience Inc. Methods and products for nucleic acid production and delivery

Also Published As

Publication number Publication date
WO2017197141A2 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
MX2022009512A (en) Targeted disruption of the mhc cell receptor.
WO2017106528A3 (en) Targeted disruption of the t cell receptor
HK1252351A1 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
IL265470B (en) Culture medium composition, and method for culturing cell or tissue using said composition
WO2016057951A3 (en) Crispr oligonucleotides and gene editing
GB2542653A (en) Methods and compositions for treating cells for transplant
EP3617309A3 (en) Crispr-based genome modification and regulation
CA2906970C (en) Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
WO2010115050A3 (en) Embryonic stem cell specific micrornas promote induced pluripotency
WO2015006498A3 (en) Therapeutic uses of genome editing with crispr/cas systems
MX351083B (en) Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers.
SG10201809566SA (en) Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof
MX2016014235A (en) Microbial ergothioneine biosynthesis.
IN2014DN09261A (en)
MX354267B (en) Modified nucleosides, nucleotides, and nucleic acids, and uses thereof.
MX2019008122A (en) Heterocycle amines and uses thereof.
WO2012106281A3 (en) Multimodal trail molecules and uses in cellular therapies
EP3442585A4 (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2011156654A3 (en) Pathways characterization of cells
WO2013188469A3 (en) Pathways characterization of cells
MX2020000154A (en) Compositions and methods for inhibiting hmgb1 expression.
WO2010132622A3 (en) Anticd20-cpg conjugates and methods of treating b cell malignancies
MX2016010100A (en) Error-free sequencing of dna.
EP3635113A4 (en) Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies
EP3246406A4 (en) Gene expression system using stealthy rna, and gene introduction/expression vector including said rna

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17796857

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 17796857

Country of ref document: EP

Kind code of ref document: A2